The process has to begin with investors who are unusually perceptive, unconventional, iconoclastic or early.

Howard Marks
What we offer

Investor Portal

Reasons to Invest

Important and unmet medical need

  • Celiac Disease and Non-Celiac Gluten Sensitivity are high unmet medical needs.
  • No effective medical curatives exist to date.

Untapped markets

  • The market size for Celiac Disease and Non-Celiac Gluten Sensitivity have a volume of USD 10.8 bn and USD 19.4 bn, respectively.
  • The awareness and diagnoses for both conditions is increasing rapidly, providing a huge opportunity for growth.

High probability of success and mitigated development risk

  • Experienced management team and major milestones already achieved
  • Validated in vitro proof of concept
  • 2-way commercialisation strategy (dietary supplement and drug)
  • GRAS notification – fast market entry as dietary supplement in USA
  • Strong IP position with patents granted in all major pharma markets
  • Lean, effective infrastructure through collaboration with leading third party research, development and pharmaceutical companies

Attractive exit opportunities

  • Ongoing M&A discussions
  • Trade sale after achievement of human proof of concept for AMY02
  • Out-licensing of AMY01 as dietary supplement



1% – 1.5%

Celiac Disease

Up to 6%

Non-Celiac Gluten Sensitivity

Number of individuals affected globally

> 0 m
Celiac Disease
> 0 m
Non-Celiac Gluten Sensitivity

Market Size

0 bn
Celiac Disease
0 bn
Non-Celiac Gluten Sensitivity

Growth Drivers

If you are interested in investing in AMYRA Biotech AG or would like to receive more information on our products and technology, please get in touch with us.